Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Timm

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Leukemia|April 27, 2007
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsM P Kline, S V Rajkumar, M M Timm, et al.
Cancers|April 14, 2025
Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid LeukemiaHusam A Jum'ah, Gregory E Otteson, Michael M Timm, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Leukemia|August 10, 2011
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphomaV Ramakrishnan, S Ansell, J Haug, et al.
Microbiome|April 24, 2020
Isolation and characterization of diverse microbial representatives from the human skin microbiomeCollin M Timm, Kristin Loomis, William Stone, et al.
Frontiers in Plant Science|November 23, 2017
Root and Rhizosphere Bacterial Phosphatase Activity Varies with Tree Species and Soil Phosphorus Availability in Puerto Rico Tropical ForestKristine G Cabugao, Collin M Timm, Alyssa A Carrell, et al.
Blood Advances|September 18, 2025
Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometryJansen N Seheult, Gregory E Otteson, Michael M Timm, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
Journal of Clinical Immunology|December 29, 2006
Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosisRoshini S Abraham, Michelle K Manske, Neta S Zuckerman, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Leukemia|April 27, 2007
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsM P Kline, S V Rajkumar, M M Timm, et al.
Cancers|April 14, 2025
Measurable Residual Disease Analysis by Flow Cytometry: Assay Validation and Characterization of 385 Consecutive Cases of Acute Myeloid LeukemiaHusam A Jum'ah, Gregory E Otteson, Michael M Timm, et al.
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Leukemia|August 10, 2011
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphomaV Ramakrishnan, S Ansell, J Haug, et al.
Microbiome|April 24, 2020
Isolation and characterization of diverse microbial representatives from the human skin microbiomeCollin M Timm, Kristin Loomis, William Stone, et al.
Frontiers in Plant Science|November 23, 2017
Root and Rhizosphere Bacterial Phosphatase Activity Varies with Tree Species and Soil Phosphorus Availability in Puerto Rico Tropical ForestKristine G Cabugao, Collin M Timm, Alyssa A Carrell, et al.
Blood Advances|September 18, 2025
Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometryJansen N Seheult, Gregory E Otteson, Michael M Timm, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
Oncogene|November 26, 2009
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsV Ramakrishnan, M Timm, J L Haug, et al.
Journal of Clinical Immunology|December 29, 2006
Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosisRoshini S Abraham, Michelle K Manske, Neta S Zuckerman, et al.
Pageof 13